Zydus' Drug for ALS Gets USFDA Fast Track, Priority Review

India's Surveillance Tools

Posted by AI on 2025-06-04 16:12:55 | Last Updated by AI on 2025-06-26 14:36:31

Share: Facebook | Twitter | Whatsapp | Linkedin Visits: 4

---

Indian pharmaceutical giant Zydus Lifesciences receives Fast Track designation from the US Food and Drug Administration (FDA) for its experimental drug Usnoflast, intended for the treatment of amyotrophic lateral sclerosis (ALS). Here's what you need to know.

Amyotrophic Lateral Sclerosis (ALS) is a progressive and often fatal neurological disease that affects the nerve cells in the brain and spinal cord, causing loss of muscle control. Zydus Lifesciences, an Indian pharmaceutical company, has developed Usnoflast, an oral NLRP3 inhibitor designed to treat the neuroinflammation associated with ALS.

Recently, the company announced that the FDA has granted Fast Track designation to Usnoflast, which is intended to accelerate the development and review process for drugs meeting serious conditions or filling an unmet medical need. This move reinforces the importance of bringing effective treatments for ALS to market. Additionally, the drug has also received Orphan Drug Designation (ODD), offering incentives such as tax credits and reduced fees to facilitate clinical testing.

Speaking on the designation, ALS Association Chairman Pankaj Patel emphasized the critical need for effective treatments for this debilitating disease. Zydus is currently undertaking a Phase 2(a) double-blind, placebo-controlled trial in India and has received approval from the FDA to commence a Phase 2(b) trial in the U.S.

Pre-clinical studies of Usnoflast have shown promise in treating not only neuroinflammation in ALS but also other conditions like Parkinson's disease, multiple sclerosis, and inflammatory bowel disease. With the fast-track designation, Zydus is poised to advance in the realm of global neurodegenerative disease treatment.

The company's dedication to developing effective treatments for debilitating diseases is commendable, and with the FDA's support, Zydus can expedite the process of making this drug available to the people who need it most.

Go!